Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR)

MLA

Piazza, R., et al. Mechanisms of Resistance to Imatinib in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Who Achieved Durable Complete Cytogenetic Responses (CCR). 2003. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1311386761&authtype=sso&custid=ns315887.

APA

Piazza, R., Magistroni, V., Tornaghi, L., Andreoni, F., Bungaro, S., Cazzaniga, G., Biondi, A., Pogliani, E., Varella Garcia, M., Corneo, G., Gambacorti Passerini, C., Piazza, R. G., Magistroni, V., Cazzaniga, G. I., Biondi, A., Pogliani, E. M., Corneo, G., & Gambacorti Passerini, C. (2003). Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR).

Chicago

Piazza, R, V Magistroni, L Tornaghi, F Andreoni, S Bungaro, G Cazzaniga, A Biondi, et al. 2003. “Mechanisms of Resistance to Imatinib in Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Who Achieved Durable Complete Cytogenetic Responses (CCR).” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1311386761&authtype=sso&custid=ns315887.